NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Generic: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE TABLETS
Mylan Pharmaceuticals Inc.Manufacturer
2018-06-22Original Approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE is FDA application ANDA205069, sponsored by XIROMED. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class III2017-01-30
Norethindrone Acetate and Ethinyl Estradiol Tablets, USP, 1 mg/0.02 mg, 1 blister pack containing 21 tablets (NDC 0378-7Chemical Contamination: out of specification results for impurities were found to be the result of c
Class II2021-07-30
Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.14 mg per day, 50/140 Twice Weekly, Rx Only a) 2 Failed Stability Specifications; out of specification for shear.
Class II2021-07-30
Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.25 mg per day 50/250 Twice Weekly Rx Only a) 2 SyFailed Stability Specifications; out of specification for shear.
Top Reported Reactions
1
NAUSEA
445 reports
2
HEADACHE
432 reports
3
HOT FLUSH
393 reports
4
FATIGUE
351 reports
5
DRUG INEFFECTIVE
316 reports
6
OFF LABEL USE
306 reports
7
PAIN
290 reports
8
ABDOMINAL PAIN
278 reports
9
VAGINAL HAEMORRHAGE
272 reports
10
ARTHRALGIA
239 reports